FDA may expand access to unapproved peptides, but safety remains unsettled
A FDA advisory panel voted to increase access to six unapproved peptides via compounding pharmacies with prescriptions, potentially changing peptide regulation. Experts caution that being more accessible does not mean these peptides are proven safe or effective—many remain untested and unregulated—though compounding could improve purity. The panel's recommendation is not final, and formal rulemaking is required; consumers should weigh potential benefits against significant safety uncertainties.
